Digoxin Injection
Product Images NDC 0404-9850

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Digoxin (NDC 0404-9850). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Henry Schein, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula1.jpg (Formula1)

FDA Label Image

Image1.jpg (Image1)

Image1.jpg (Image1)
This is a table showing the recommended Digoxin Injection Loading Dose in micrograms per kilogram (MCG/KG) for adult patients weighing between 8-12 kilograms. It recommends administering half of the total loading dose initially and then administering the remaining half of the loading dose every 6-8 hours twice.*
FDA Label Image

Image2.jpg (Image2)

Image2.jpg (Image2)
This text provides a table of recommended starting digoxin injection maintenance dosage for adult patients. It includes the total intravenous maintenance dose, given once daily, and clarifies that MCG stands for microgram.*
FDA Label Image

Image3.jpg (Image3)

Image3.jpg (Image3)
The text provides a table that shows the recommended maintenance dose of Digoxin Injection for adult patients based on lean body weight and renal function. The table presents the dosages in micrograms given once daily for different bodyweight categories and number of days. The dosage values are dependent on renal function expressed in mL/min, corrected creatinine clearance, and estimated Glomerular Filtration Rate (GFR). The table also offers formulas for estimating creatinine clearance and GFR in patients with serum creatinine concentration. The text provides necessary information for prescribing Digoxin Injection for adults and offers formulas for estimating renal function in the absence of creatinine clearance values.*
FDA Label Image

Image4.jpg (Image4)

Image4.jpg (Image4)
This is a table that compares the systemic availability and equivalent dosages in micrograms of oral and intravenous administration of a drug called Avarlahuny. The drug is available in both Ldinuxin tablet form (with a bioavailability of 60-80%) and Joxin intravenous injection form (with a bioavailability of 100%). The table displays the equivalent dosage amounts for different strengths of both forms of administration.*
FDA Label Image

Image5.jpg (Image5)

Image5.jpg (Image5)
This is a document discussing the effects of certain drugs on digoxin concentrations in the blood. It provides recommendations for measuring digoxin concentrations and reducing them in cases where they increase more than 50%. It also lists drugs that have a minor effect on digoxin exposure and do not require any additional actions.*
FDA Label Image

Image6.jpg (Image6)

Image6.jpg (Image6)
This text seems to be a medical article on drugs that affect the function of digoxin. Various drugs and their interactions with digoxin have been discussed. The article mentions that drugs such as Adectine, ACE inhibitors, and nonsteroidal anti-inflammatory drugs can impair the excretion of digoxin. Similarly, the article explains the interactions between digoxin, Sotalol, Dronedaro, Parathyrl, Thyroid, and Neuroms. The text also emphasizes that the use of certain drugs in combination with digoxin can cause sudden death and abnormal heart rhythms, and increase the dose requirements of digoxin. Thus, the article sheds light on the effective administration of various drugs concerning digoxin.*
FDA Label Image

Image8.jpg (Image8)

Image8.jpg (Image8)
Table 5 shows the times it takes for different preparations of Digoxin to take effect and reach peak effectiveness. The onset of effect for Digoxin tablets is between 0.5-2 hours, while the onset of effect for Digoxin injection/IV is between 5-30 minutes. These times are documented with respect to ventricular response rate in atrial fibrillation, inotropic effects, and electrocardiographic changes. However, the time to peak effect depends on the rate of infusion.*
FDA Label Image

Label1.jpg (Label1)

Label1.jpg (Label1)
This is a description of a medication called Digoxin. It comes in a 2mL ampul at a concentration of 250mg/mL. It is used for slow intravenous or deep intramuscular use, and does not require dilution. The ampul should be opened by breaking at the constriction. It should be kept out of children's reach, stored at 20-25C (68-77F), and is only available with a prescription. The manufacturer is identified as West-Ward and on the box there is a GTIN code, series number and lot number.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.